Influence of Myeloid-derived Suppressor Cells in Tumor Immunotherapy

Yang Yu

doi:10.62051/m3esma61

Authors

Yang Yu

DOI:

https://doi.org/10.62051/m3esma61

Keywords:

MDSC, Immunosuppressive mechanisms, ARG1, small molecule inhibitors, CB-1158r.

Abstract

The immunosuppressive response of myeloid-derived suppressor cells (MDSCs) in tumor microenvironment (TME) has become an important area of tumor research. Among them, arginase 1 (ARG1), as a key immunosuppressive molecule in MDSCs, inhibits T cell function by consuming L-arginine, producing polyamines and secreting immunosuppressive cytokines, thereby promoting tumor immune escape. This article first briefly introduces the background and mechanism of action of MDSCs, and then systematically summarizes and analyzes the fine regulation of ARG1 expression by multiple factors, including transcriptional, epigenetic and post-translational mechanisms, and its specific role in MDSCs and its regulatory mechanism. Finally, the research progress of ARG1 as a potential therapeutic target is summarized, such as the development and application of ARG1 inhibitors, and the mechanisms of action and advantages and disadvantages of several different research methods are analyzed. A promising small molecule inhibitor CB-1158 and future prospects are understood, and the therapeutic direction and possible solutions for future research are proposed.

Downloads

Download data is not yet available.

References

[1] Veglia, F., M. Perego, and D. Gabrilovich, Myeloid-derived suppressor cells coming of age. Nature immunology, 2018. 19(2): p. 108-119.

[2] Niu, F., et al., Arginase: An emerging and promising therapeutic target for cancer treatment. Biomed Pharmacother, 2022. 149: p. 112840.

[3] Jou, E., N. Chaudhury, and F. Nasim, Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment. Explor Target Antitumor Ther, 2024. 5(1): p. 187-207.

[4] Grzywa, T.M., et al., Myeloid Cell-Derived Arginase in Cancer Immune Response. Front Immunol, 2020. 11: p. 938.

[5] Bansal, V. and J.B. Ochoa, Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care, 2003. 6(2): p. 223-8.

[6] Wu, Y., et al., Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Molecular Cancer, 2022. 21(1): p. 184.

[7] Hegde, S., A.M. Leader, and M. Merad, MDSC: Markers, development, states, and unaddressed complexity. Immunity, 2021. 54(5): p. 875-884.

[8] Geiger, R., et al., L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell, 2016. 167(3): p. 829-842.e13.

[9] Rodriguez, P.C., D.G. Quiceno, and A.C. Ochoa, L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 2007. 109(4): p. 1568-73.

[10] Raber, P., A.C. Ochoa, and P.C. Rodríguez, Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest, 2012. 41(6-7): p. 614-34.

[11] Groth, C., et al., Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer, 2019. 120(1): p. 16-25.

[12] Fletcher, M., et al., l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res, 2015. 75(2): p. 275-83.

[13] Arlauckas, S.P., et al., Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics, 2018. 8(21): p. 5842.

[14] Rodríguez, P.C. and A.C. Ochoa, Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev, 2008. 222: p. 180-91.

[15] Bin Sawad, A., et al., Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review. Mol Genet Metab, 2022. 137(1-2): p. 153-163.

[16] Sosnowska, A., et al., Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. Oncoimmunology, 2021. 10(1): p. 1956143.

[17] Li, Q., et al., Arginase-1 promotes lens epithelial-to-mesenchymal transition in different models of anterior subcapsular cataract. Cell Communication and Signaling, 2023. 21(1): p. 236.

[18] Steggerda, S.M., et al., Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer, 2017. 5(1): p. 101.

[19] Yap, T.A., et al., Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov, 2021. 11(6): p. 1368-1397.